<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065987</url>
  </required_header>
  <id_info>
    <org_study_id>01221</org_study_id>
    <nct_id>NCT01065987</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Tizanidine Hydrochloride 4mg Tablets and Zanaflex® 4mg Tablets Administered As 1 x 4mg Tablet in Healthy Adult Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this bioequivalence study is to compare the test tizanidine Hydrochloride 4mg
      tablets of Dr.Reddys Laboratories Limited with reference zanaflex® 4mg tablets of Elan in
      healthy adult subjects under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, 2-way crossover, bioequivalence study of tizanidine Hydrochloride 4mg tablets and
      zanaflex® 4mg tablets administered As 1 x 4mg tablet in healthy adult subjects under fed
      conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">November 2001</completion_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study of Tizanidine HCl Tablets 4 mg of Dr.Reddy's Laboratories Limited under Fed Conditions</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tizanidine HCl 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zanaflex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zanaflex 4 mg Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tizanidine</intervention_name>
    <description>Tizanidine HCl Tablets 4 mg</description>
    <arm_group_label>Tizanidine HCl 4 mg</arm_group_label>
    <arm_group_label>Zanaflex</arm_group_label>
    <other_name>Zanaflex 4 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects enrolled in this study will be members of the community at large. The recruitment
        advertisements may be done using different media (e.g. radio, newspaper, Anapharm Inc.

        Web site). Subjects must meet all of the following criteria in order to be included in the
        study:

          -  Subjects will be females and/or males, smokers or non-smokers, 18 years of age and
             older.

          -  Female subjects will be post-menopausal or surgically sterilized.

               -  Post-menopausal status is defined as absence of menses for the past 12 months.

               -  Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal
                  ligation at least 6 months ago.

        Exclusion Criteria:

        Subjects to whom any of the following applies will be excluded from the study:

          -  Clinically significant abnormalities found during medical screening.

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication.

        Clinically significant illnesses within 4 weeks of the administration of study medication.

          -  History of neuromuscular disease.

          -  Abnormal laboratory tests judged clinically significant.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 100 or over 140 mmHg, or diastolic blood pressure lower than 70 or
             over 90; or heart rate less than 60 bpm) at screening.

          -  Subjects with BMI ≥ 30.0.

          -  History of allergic reactions to tizanidine hydrochloride.

          -  Any food allergies, intolerances, restrictions, or special diet which in the opinion
             of the medical sub investigator, contraindicates the subject's participation in this
             study.

          -  Positive urine drug screen at screening.

          -  Positive testing for hepatitis B, hepatitis C or HN at screening.

          -  Positive urine pregnancy test at screening.

          -  Donation of plasma (500 mL) within 7 days or donation or significant loss of whole
             blood (500 mL) within 56 days prior to administration of the study medication.

          -  History of significant alcohol abuse within six months of the screening visit or any
             indication of the regular use of more than two units of alcohol per day (l Unit = 150
             mL of wine or 360 mL of beer or 45 mL of alcohol 40%).

          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana,
             pot) within 3 months of the screening visit or hard drugs (such as cocaine,
             phencyclidine (PCP) and crack) within 1 year of the screening visit.

          -  Subjects who have taken prescription medication within 14 days prior to administration
             of study medication or over-the-counter products within 7 days prior to administration
             of study medication, except for topical products without systemic absorption.

          -  Smoking more than 25 cigarettes per day.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;
             examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin,
             ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine), use of an
             investigational drug or participation in an investigational study within 30 days prior
             to administration of the study medication.

          -  Any reason which, in the opinion of the medical sub investigator, would prevent the
             subject from participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Sainte-Foy (Quebec)</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>February 8, 2010</last_update_submitted>
  <last_update_submitted_qc>February 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Assistant Manager</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tizanidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

